Terns Pharma completes NASH trial enrollment, on track for CML and obesity trials in H2 2023

Terns Pharmaceuticals, Inc.

Completed enrollment in Phase 2a DUET trial of TERN-501 (THR-β agonist) for NASH; top-line data expected Q3 2023.
On track to initiate U.S. Phase 1 trial for TERN-701 (allosteric BCR-ABL inhibitor) in CML in H2 2023; China Phase 1 update at major oncology conference.
IND-enabling activities for TERN-601 (oral GLP-1R agonist) ongoing; first-in-human obesity trial expected H2 2023 with top-line data in 2024.
FDA Type C meeting scheduled for May 2023 to discuss non-invasive endpoints for NASH development.
Adjusted cash balance of $293M (including $112M Dec 2022 equity financing) expected to provide runway into 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.